Parkinson's disease (PD) is the second most common neurodegenerative disease affecting 1 % of the population above the age 65. 1 The incidence of PD is expected to increase dramatically worldwide with increased life expectancy. 2 PD is manifested by the combination of primary motor disability (bradykinesia, rigidity, tremor, and gait impairment) as well as a spectrum of non-motor symptoms including cognitive, mood, autonomic, and sleep dysfunction. 3 The cause of cells degeneration in PD remains unknown. While there is a widespread distribution of neuropathologic changes in the brain responsible for the spectrum of the motor and non-motor manifestations of PD, degeneration of dopamine-producing cells in the substantia nigra pars compacta (SNc) is central to the primary motor signs of the disease. 
the protein α-synuclein, 4 which appears to have a role in the release of neurotransmitter from synaptic terminals. 5 One proposed mechanism is α-synuclein-induced impairment of the ubiquitin-proteasomal system (UPS), resulting in protein accumulation and leading to cell degeneration. 6 LBs are widely distributed in the brains of PD patients, including the SNc, raphe nucleus, locus ceruleus, pedunculopontine nucleus, dorsal motor nucleus of vagus, olfactory bulb, and some cortical structures. 7 While the neuropathologic changes in PD are widespread and include a number of neurotransmitter pathways, the cardinal motor manifestations of the disease are clearly linked to the degeneration of the dopamine-producing cells in the SNc. Some of the postulated mechanisms of SNc cells' death is oxidative stress and complex I mitochondrial dysfunction. 8 A mitochondrial linkage is supported by the recent advances in the knowledge of the genetic mutations associated with the rare familial forms of PD. Several of PD genes have a role in mitochondrial function. PINK1, DJ-1, and LRKK2 encode proteins that are localized to the surface or in the mitochondria. [9] [10] [11] Rotenone, paraquat, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxins that produce animal models of parkinsonism are believed to work via mitochondrial complex I inhibition. 10 Mitochondrial dysfunction leads to the generation of reactive oxygen species (ROS), that are cytotoxic and can lead to the formation of LB-like intraneuronal filamentous inclusions, containing α-synuclein and ubiquitin. 12, 13 It is believed that all the above postulated pathogenic factors result in a common pathway of cell degeneration by mechanism of apoptosis. 
Substantia Nigra Pars Compacta Cells Pacemaking and Mitochondrial Oxidant Stress
When neurons generate spikes, the transmembrane ionic gradients that enable this activity are dissipated. These gradients must be restored with ATP-dependent pumps and exchangers. Thus, sustained activity is energetically expensive. Ca 2+ ions, because they must be rapidly sequestered or pumped back across the plasma membrane, could pose a particularly significant energetic burden. In neurons, this demand for ATP is met primarily by oxidative phosphorylation in mitochondria. 30 Oxidative phosphorylation comes at a cost: the production of potentially damaging superoxide and reactive oxygen species.
Recent studies by our group have shown that Ca 2+ entry through L-type channels elevates mitochondrial oxidant stress in SNc DA neurons. 24 Moreover, systemic administration of isradipine to mice at doses achieves serum concentrations in the same range as those found in humans following oral administration protects SNc DA neurons in both a chronic MPTP and acute 6-hydroxydopamine (6-OHDA) models. 24, 32 Although these channels participate in normal pacemaking, they are not essential and antagonizing them with therapeutically relevant concentrations of dihydropyridine has no effect on the rest of the mouse behavior or phenotype. 
Epidemiologic Studies
Recent epidemiologic data also supports the potential neuroprotective 
Preliminary Human Data
We have conducted an open-label dose escalation safety and tolerability study of isradipine in patients with early PD. The study demonstrated dose-dependent tolerability of isradipine CR: 94 % for a 5 mg dose; 87 % for a 10 mg dose; 68 % for a 15 mg dose; and 52 % for a 20 mg dose. 43 Isardipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (seven) and dizziness (three). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment.
That study supports good tolerability of isradipine CR at daily doses up to 10 mg in subjects with early PD. of isradipine CR or matching placebo daily. The dosage that is tolerable and demonstrates preliminary efficacy will be used in the future pivotal efficacy study. 44 Tolerability of each active dosage will be compared with the tolerability of placebo. Provided that the dose is tolerable, the choice for the dose selection will be based on efficacy defined as the change in total UPDRS score between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy, whichever occurs first. Comparison will be made between three active treatment arms. The dosage that demonstrates the greatest efficacy will be used in the proposed pivotal study. The study has successfully completed recruitment, with the final data analysis expected to be available in the next six months.
Conclusion
There is solid scientific rationale, preclinical, and epidemiologic data to support the potential benefit of isradipine as a disease modifying agent in early PD. Results of the ongoing Phase II study will be available shortly and will inform the design of the future pivotal efficacy trial. n
